Arcturus Therapeutics Says Phase 2 Interim Results of ARCT-810 Showed Reduced Glutamine Levels in OTC Deficiency

MT Newswires Live

Jun 30, 2025

Arcturus Therapeutics (ARCT) said Monday that its mRNA therapeutic candidate, ARCT-810, showed "significant and consistent" reduction and normalization of abnormally elevated glutamine, according to interim data from a phase 2 trial.

The drug candidate is intended for the treatment of OTC deficiency, a genetic disorder.

The company reported the first significant relative ureagenesis function improvements using a new and optimized 15N-ureagenesis assay.

Meanwhile, multiple administrations of ARCT-810 continued to be safe and well tolerated at all tested dose levels, the company said.

Shares of Arcturus gained more than 2% in recent trading activity Monday.

Price: 13.61, Change: +0.28, Percent Change: +2.10

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2547015255"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2547015255\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2547015255?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-30 23:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2547015255","market":"sg","top_or_hot":-1,"title":"Arcturus Therapeutics Says Phase 2 Interim Results of ARCT-810 Showed Reduced Glutamine Levels in OTC Deficiency","media":"MT Newswires Live","content":"<html><body><p> Arcturus <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (ARCT) said Monday that its mRNA therapeutic candidate, ARCT-810, showed \"significant and consistent\" reduction and normalization of abnormally elevated glutamine, according to interim data from a phase 2 trial.</p><p>The drug candidate is intended for the treatment of OTC deficiency, a genetic disorder.</p><p>The company reported the first significant relative ureagenesis function improvements using a new and optimized 15N-ureagenesis assay.</p><p>Meanwhile, multiple administrations of ARCT-810 continued to be safe and well tolerated at all tested dose levels, the company said.</p><p>Shares of Arcturus gained more than 2% in recent trading activity Monday.</p><p>Price: 13.61, Change: +0.28, Percent Change: +2.10</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Arcturus Therapeutics Says Phase 2 Interim Results of ARCT-810 Showed Reduced Glutamine Levels in OTC Deficiency</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nArcturus Therapeutics Says Phase 2 Interim Results of ARCT-810 Showed Reduced Glutamine Levels in OTC Deficiency\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-06-30 23:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Arcturus <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (ARCT) said Monday that its mRNA therapeutic candidate, ARCT-810, showed \"significant and consistent\" reduction and normalization of abnormally elevated glutamine, according to interim data from a phase 2 trial.</p><p>The drug candidate is intended for the treatment of OTC deficiency, a genetic disorder.</p><p>The company reported the first significant relative ureagenesis function improvements using a new and optimized 15N-ureagenesis assay.</p><p>Meanwhile, multiple administrations of ARCT-810 continued to be safe and well tolerated at all tested dose levels, the company said.</p><p>Shares of Arcturus gained more than 2% in recent trading activity Monday.</p><p>Price: 13.61, Change: +0.28, Percent Change: +2.10</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2547015255","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2547015255","pubTimestamp":1751297928,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Arcturus Therapeutics  said Monday that its mRNA therapeutic candidate, ARCT-810, showed \"significant and consistent\" reduction and normalization of abnormally elevated glutamine, according to interim data from a phase 2 trial.The drug candidate is intended for the treatment of OTC deficiency, a genetic disorder.The company reported the first significant relative ureagenesis function improvements using a new and optimized 15N-ureagenesis assay.Meanwhile, multiple administrations of ARCT-810 continued to be safe and well tolerated at all tested dose levels, the company said.Shares of Arcturus gained more than 2% in recent trading activity Monday.Price: 13.61, Change: +0.28, Percent Change: +2.10","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","ARCT":"Arcturus Therapeutics Ltd."},"translate_title":"Arcturus Therapeutics表示ARCT-810的2期中期结果显示OTC缺乏症患者的谷氨酰胺水平降低","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ARCT":1},"content_text":"Arcturus Therapeutics (ARCT) said Monday that its mRNA therapeutic candidate, ARCT-810, showed \"significant and consistent\" reduction and normalization of abnormally elevated glutamine, according to interim data from a phase 2 trial.The drug candidate is intended for the treatment of OTC deficiency, a genetic disorder.The company reported the first significant relative ureagenesis function improvements using a new and optimized 15N-ureagenesis assay.Meanwhile, multiple administrations of ARCT-810 continued to be safe and well tolerated at all tested dose levels, the company said.Shares of Arcturus gained more than 2% in recent trading activity Monday.Price: 13.61, Change: +0.28, Percent Change: +2.10","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}